<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382937</url>
  </required_header>
  <id_info>
    <org_study_id>A14-301</org_study_id>
    <nct_id>NCT04382937</nct_id>
  </id_info>
  <brief_title>Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection</brief_title>
  <official_title>An Open-label, Randomized, Active Control Study to Demonstrate Non-Inferiority in Efficacy, and to Compare Safety and Tolerability of P1101 + Ribavirin to PEG-Intron + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic HCV Genotype 2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaEssentia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinipace Worldwide</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PharmaEssentia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To demonstrate non-inferiority in sustained virologic response (SVR, undetectable HCV RNA at&#xD;
      Follow up week 12) between PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily&#xD;
      and P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily for the treatment of chronic HCV&#xD;
      genotype 2 infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objective:&#xD;
&#xD;
      To determine and compare the efficacy, safety, tolerability and immunogenicity of PEG-Intron&#xD;
      1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily and P1101 400 µg SC Q2W + Ribavirin&#xD;
      800-1400 mg PO daily&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2016</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects with undetectable serum HCV RNA at follow up week 12</measure>
    <time_frame>Follow Week 12</time_frame>
    <description>Percentage of subjects with SVR12 (undetectable serum HCV RNA, i.e. &lt;12 IU/mL, at follow up week 12) in each treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects with undetectable serum HCV RNA</measure>
    <time_frame>Treatment Week 4, 8, 12, 24 and Follow Week 24</time_frame>
    <description>Percentage of subjects with undetectable serum HCV RNA at treatment week 4, 8, 12, 24 (end of treatment) and follow up week 24 in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Through study Follow Week 24</time_frame>
    <description>Number of subjects with adverse events in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant laboratory abnormalities</measure>
    <time_frame>Through study Follow Week 24</time_frame>
    <description>Number of subjects with clinically significant laboratory abnormalities in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with anti-drug antibodies</measure>
    <time_frame>Follow Week 12 and 24</time_frame>
    <description>Percentage of subjects with positive anti-drug antibodies (the anti-peginterferon and the anti-Peg) at follow up week 12 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with neutralizing antibody</measure>
    <time_frame>Follow Week 12 and 24</time_frame>
    <description>Percentage of subjects with positive neutralizing antibody at follow up week 12 and 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Chronic Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>P1101 + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P1101 400 µg SC Q2W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-Intron + Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEG-Intron 1.5 µg per kg SC Q1W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P1101 + Ribavirin</intervention_name>
    <description>P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily</description>
    <arm_group_label>P1101 + Ribavirin</arm_group_label>
    <other_name>Ropeginterferon alfa-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-Intron + Ribavirin</intervention_name>
    <description>PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily</description>
    <arm_group_label>PEG-Intron + Ribavirin</arm_group_label>
    <other_name>Peginterferon alfa-2b</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults ≥18 years of age (or other age required by local regulations); subjects who are&#xD;
             over 70 years of age must be in generally good health.&#xD;
&#xD;
          2. Confirmed diagnosis of chronic hepatitis with HCV genotype 2 infection. Chronicity is&#xD;
             defined as having proven clinical evidence of chronic hepatitis, e.g. a duration of&#xD;
             disease longer than 24 weeks before dosing, OR positive for anti-HCV antibody and HCV&#xD;
             RNA at screening with biopsy-proven chronic hepatitis C, OR fibrosis.&#xD;
&#xD;
          3. Compensated liver disease defined by normal or elevated ALT ≤10 x ULN, total bilirubin&#xD;
             level &lt;2 mg/dL (except in Gilbert's syndrome), normal albumin, normal INR (INR ≤1.5)&#xD;
&#xD;
          4. Interferon treatment naïve: never received any interferon.&#xD;
&#xD;
          5. No other known form of chronic liver disease apart from chronic hepatitis C infection.&#xD;
             But mild and moderate fatty liver diseases can be included.&#xD;
&#xD;
          6. Hemoglobin ≥12 g/dL in men or ≥11 g/dL in women, WBC count ≥3,000/mm3, ANC ≥1,500/mm3,&#xD;
             platelet count ≥90,000/mm3; and estimated glomerular filtration rate &gt;60 mL/min.&#xD;
&#xD;
          7. Female and male subjects, and their partners of reproductive potential using effective&#xD;
             means of contraception during the whole trial period.&#xD;
&#xD;
          8. Be able to attend all scheduled visits and to comply with all study procedures;&#xD;
&#xD;
          9. Be able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of the following is cause for exclusion from the study:&#xD;
&#xD;
          1. Decompensated liver disease, including overt clinical symptom and sign of&#xD;
             complications related to portal hypertension.&#xD;
&#xD;
          2. Clinically significant illness or surgery within 4 weeks prior to dosing.&#xD;
&#xD;
          3. Any reason which, in the opinion of the investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
&#xD;
          4. Positive test for hepatitis B surface antigen or human immunodeficiency virus at&#xD;
             screening.&#xD;
&#xD;
          5. Clinically significant abnormal vital signs at screening.&#xD;
&#xD;
          6. Evidence of severe retinopathy by fundoscopy except age-related macular degeneration&#xD;
             at screening.&#xD;
&#xD;
          7. Significant alcohol or illicit drug abuse within one year prior to the screening visit&#xD;
             or refusal to abstain from excessive alcohol consumption as defined above or illicit&#xD;
             drugs throughout the study.&#xD;
&#xD;
          8. Pregnant or breast feeding female subjects.&#xD;
&#xD;
          9. Therapy with any systemic anti-viral, anti-neoplastic, and immunomodulatory treatment&#xD;
             (including supraphysiologic doses of steroids and radiation) within 4 weeks prior to&#xD;
             the first dose of study drug.&#xD;
&#xD;
         10. Use of an investigational drug or participation in an investigational drug trial&#xD;
             within 4 weeks from the first dose.&#xD;
&#xD;
         11. Known clinically significant presence of any gastrointestinal pathology, clinically&#xD;
             significant unresolved gastrointestinal symptoms, clinically significant liver (other&#xD;
             than CHC) or clinically significant kidney disease (including but not limited to those&#xD;
             with chronic renal failure on dialysis), or other conditions known to interfere with&#xD;
             the absorption, distribution, metabolism, or excretion of the drug.&#xD;
&#xD;
         12. Hospital Anxiety and Depression Scale (HADS) score &gt;10 on depression scale at&#xD;
             screening that indicates clinically significant presence of depression determined by&#xD;
             investigators.&#xD;
&#xD;
         13. Clinically significant presence of severe neurological disorders, e.g. uncontrolled&#xD;
             seizure disorders.&#xD;
&#xD;
         14. Clinically significant presence of severe cardiovascular conditions and severe&#xD;
             pulmonary conditions (including but not limited to pulmonary infiltrates, pneumonia,&#xD;
             pneumonitis, chronic obstructive lung disease), uncontrolled immunologic, uncontrolled&#xD;
             autoimmune, uncontrolled endocrine, uncontrolled metabolic, haematological, severe&#xD;
             coagulation disorders or severe blood dyscrasias or other severe uncontrolled systemic&#xD;
             disease.&#xD;
&#xD;
         15. A depot injection or an implant of any drug within 3 months prior to administration of&#xD;
             study medication, other than contraception or hyaluronic acid injections in joints for&#xD;
             osteoarthritis;&#xD;
&#xD;
         16. Body organ transplant and are taking immunosuppressants;&#xD;
&#xD;
         17. History of malignant disease, including solid tumors and hematologic malignancies&#xD;
             (except basal cell and squamous cell carcinomas of the skin that have been completely&#xD;
             excised and are considered cured, and carcinoma in situ of cervix); However, subjects&#xD;
             who are cancer survivors not on maintenance therapy and who had no malignant diseases&#xD;
             history within the past 5 years could be recruited.&#xD;
&#xD;
         18. History of or ongoing opportunistic infection.&#xD;
&#xD;
         19. Serious local infection or systemic infection within the 3 months prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Wen Huang, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>PharmaEssentia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Ditan Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gansu Wuwei Tumour Hospital</name>
      <address>
        <city>Gansu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Gansu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Henan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luoyang Central Hospital</name>
      <address>
        <city>Henan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peace Hospital Affiliated to Changzhi Medical College</name>
      <address>
        <city>Shanxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Seoul Hospital</name>
      <address>
        <city>Asan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Metropolitan Government - Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Catholic Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Chiayi Branch</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chia-Yi Christian Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalin Tzu Chi Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Martin De Porres Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hualien Tzu Chi Hospital</name>
      <address>
        <city>Hualien City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Keelung Branch</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital, Liouying</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taitung MacKay Memorial Hospital</name>
      <address>
        <city>Taitung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital Yun-Lin Branch</name>
      <address>
        <city>Yuanlin</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P1101</keyword>
  <keyword>HCV</keyword>
  <keyword>PEG-Intron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

